Australia Infection Control Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Product (Disinfectants, Sterilization (Low-Temperature Sterilization, Heat Sterilization, Contract Sterilization)), By End User Industry (Healthcare, Food And Beverage, Chemical) - Forecasts From 2022 To 2027

Australia’s infection control market is evaluated at US$356.839 million for the year 2020 and is projected to grow at a CAGR of 5.16% to reach a market size of US$507.595 million by the year 2027. The advanced healthcare system in Australia is projected to boost the growth of the infection control market in the country during the forecast period. The growing geriatric population and the increasing prevalence of chronic diseases are driving the market demand with the increasing number of visits for diagnosis, treatment, and post-treatment care. Additionally, with advancements in medical research and innovations in the medical industry, the market is estimated to grow at a high growth rate in the forecast period. Furthermore, with the emergence of new technologies in healthcare, the country is geared towards the effective utilization of these novel technologies, which will have a strong impact on the health of Australian citizens and the medical services provided to these individuals. The novel technologies range from digital health technologies to automated health and diagnostic services, thus, impacting positively the growth of the infection control industry in the forecast period.

The presence of primary health networks (PHNs) in the country is propelling the market growth in the forecast period.

According to the Australian Government Department of Health, there are 31 primary health networks in the country. Primary health networks (PHNs) are referred to as organizations responsible for coordinating health services in the local areas of the country. These are known to support community health centres, hospitals, GPs, specialists, and other health professionals in the improvement of patient care. These coordinate the different stages of the health system, examples include, the coordination between the hospital and the doctor at the time of patient discharge. PHNs are also involved in the assessment of the health needs of individuals in their local area. The provision of extra services, including after-hours services, mental health services, health promotion programs, and support for primary care (GPs) which include continuing education, is also providing an opportunity for the market to grow in the forecast period and in the upcoming years owing to the use of infection control products in several ongoing healthcare activities. 

The growing medical research and innovation in Australia are driving the market demand in the forecast period and in the upcoming years. 

Certain strategies, including the Australian Medical Research and Innovation Strategy 2016-2021, are encouraging the growth of medical research and innovation in the country. Hence the infection control market is estimated to hold strong growth prospects to burgeon in the forecast period and in the coming years. The innovation strategy mentioned above, designed by the Australian Medical Research Advisory Board, is aimed at achieving certain objectives through six platforms. This includes strategic and international horizons, resulting in leading and collaborating with international health and medical research. The other platform including data and infrastructure, deals with the integration of the health data framework for supporting healthcare delivery, service improvement, and adoption of best healthcare practices. Other platforms consist of capacity and collaboration, health services and systems, trials and translation, and commercialization, further providing an opportunity for the market to flourish in the forecast period and in the upcoming years.

KEY DEVELOPMENT

• April 2020- The first Australian product that can legitimately claim to destroy COVID-19 was created by a business in New South Wales. The Whiteley Corporation's Hunter Valley factory produces the hospital-grade disinfectant Viraclean, which is the first locally produced item of its sort to receive approval from the Therapeutic Goods Administration (TGA).

COVID-19 SCENARIO

In response to the COVID-19 pandemic, the producers of infection control products are increasing their production capacity to produce medical nonwoven gloves and other primary infectious control gears. The demand for protective barrier items and disposable medical supplies is predicted to increase due to the rise of COVID-19 cases and the increased demand for healthcare workers. Patient-to-patient infection dissemination via medical devices during the outbreak can be completely avoided by adequately sanitizing medical equipment. Due to the potential risk of COVID-19 from improperly decontaminating surgical instruments, endoscopic devices, respiratory care equipment, and reusable hemodialysis machines, the use of reprocessed equipment to disinfect or sterilise medical devices is higher than usual during pandemics. Ensuring the appropriate sterilisation of medical devices has led to increasing in the demand for sterilisation consumables. Therefore, during the predicted period, COVID-19 infection increased growth and prospects for makers of infection control products.

Australia Infection Control Market Scope:

Market Segmentation:

• By Product
  • Disinfectant
  • Sterilization
    • Low-temperature Sterilization
    • Heat Sterilization
    • Contract Sterilization
  • Others
• By End User Industry
  • Healthcare
  • Food and Beverage
  • Chemical